GlassScriptPhysician profile
Brian William Cooper
NPI 1023032307
$3,435.01
in general payments reported to CMS, 2019-2025
23 companies · $30.05 in 2025
The $30.05 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $650 · 2021: $905 · 2022: $499 · 2023: $24.66 · 2024: $136 · 2025: $30.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $190.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $599.92 | 2019-2022 | |
| Gilead Sciences, INC. | $515.91 | 2019-2022 | |
| Viiv Healthcare Company | $467.52 | 2019-2022 | |
| Allergan, INC. | $272.88 | 2019-2020 | |
| Abbvie INC. | $239.01 | 2021-2024 | Avycaz |
| Janssen Products, LP | $213.25 | 2019-2022 | |
| Theratechnologies INC. | $187.69 | 2019-2021 | |
| Janssen Biotech, INC. | $180.11 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $140.49 | 2022 | |
| Comsort, INC | $100.00 | 2019 | |
| Melinta Therapeutics, LLC | $74.91 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $70.94 | 2020-2021 | |
| Tetraphase Pharmaceuticals, INC. | $68.99 | 2019-2020 | |
| Insmed, INC. | $59.49 | 2019-2021 | |
| Shionogi INC | $52.22 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $46.72 | 2024-2025 | Menopur |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Sobi, INC | $25.58 | 2020 | |
| Daiichi Sankyo INC. | $24.59 | 2021 | |
| Biocomposites INC | $19.93 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $16.75 | 2020 | |
| Horizon Therapeutics Plc | $14.83 | 2019 | |
| Organogenesis INC. | $14.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.